Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood

New England Journal of Medicine, 2017

The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, University Hospital Schleswig-Holstein, University of Lübeck, Mylan (Switzerland), Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Queensland, Gallipoli Medical Research Foundation, Ospedale Papa Giovanni XXIII, Royal Marsden NHS Foundation Trust, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, The Alfred Hospital, Institut Gustave Roussy, Centre Hospitalier Universitaire de Lille, Université de Lille, Sheba Medical Center, Deutschen Konsortium für Translationale Krebsforschung, German Cancer Research Center, Centre Eugène Marquis, Freeman Hospital, Westmead Hospital, Macquarie University, University Hospital of Zurich, UPMC Hillman Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1464

Citations

View on Google Scholar

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Abstract

Journal Details

Join JournalsHub

Welcome Back